Compare UTHR & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | HII |
|---|---|---|
| Founded | 1996 | 1886 |
| Country | United States | United States |
| Employees | N/A | 44000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 17.4B |
| IPO Year | 1999 | 2010 |
| Metric | UTHR | HII |
|---|---|---|
| Price | $500.47 | $442.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $520.00 | $379.50 |
| AVG Volume (30 Days) | 307.6K | ★ 548.9K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.25% |
| EPS Growth | ★ 13.07 | 10.24 |
| EPS | ★ 27.86 | 15.39 |
| Revenue | $1,483,300,000.00 | ★ $12,484,000,000.00 |
| Revenue This Year | $8.56 | $4.58 |
| Revenue Next Year | $10.71 | $6.30 |
| P/E Ratio | ★ $18.21 | $28.83 |
| Revenue Growth | 2.38 | ★ 8.23 |
| 52 Week Low | $266.98 | $167.70 |
| 52 Week High | $537.19 | $451.86 |
| Indicator | UTHR | HII |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 60.91 |
| Support Level | $463.06 | $263.18 |
| Resistance Level | $516.36 | N/A |
| Average True Range (ATR) | 17.02 | 15.98 |
| MACD | 3.90 | 1.21 |
| Stochastic Oscillator | 50.18 | 86.96 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.